Single-dose tranexamic acid for reducing bleeding and transfusions in total hip arthroplasty: A double-blind, randomized controlled trial of different doses

124 patients scheduled for total hip arthroplasty were randomized to one of three groups: a single intravenous dose of 10mg/kg tranexamic acid (TXA); a single intravenous dose of 15mg/kg TXA; or a single intravenous dose of placebo saline. The purpose of this study was to examine and compare efficacy and safety outcomes between groups. While both TXA groups demonstrated a significant reduction in total blood loss, postoperative drainage volume, and hemoglobin drop compared to placebo, total blood loss and postoperative drainage volume was significantly lower in the 15mg/kg group compared to the 10mg/kg. Additionally, only the 15mg/kg group demonstrated a significant reduction in transfusion incidence compared to the placebo group. Thromboembolic events were similar between the three groups.